Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com/ and get exclusive access to our numerous stock reports.

Dendreon Corporation (NASDAQ: DNDN) shares spiked 11.26 percent to close at $2.81 a share Monday. The stock traded between $19.00 and $20.14 on volume 15.36 million shares traded. Bloomberg news has reported the company is working with JPMorgan Chase & Co. to find potential suitors. Shares of Dendreon have fallen approximately 46.0 percent year-to-date.

Get more information on Dendreon and free access to the in-depth equity report at:
www.FiveStarEquities.com/DNDN

Edwards Lifesciences Corp. (NYSE: EW) shares dropped 4.70 percent to close at $73.44 a share Monday. The stock traded between $71.81 and $75.06 on volume of 2.94 million shares traded. The company reported a net income of $77.0 million for the third quarter of 2013, compared to $69.0 million a year ago. Shares of Edwards Lifesciences have fallen approximately 18.0 percent year-to-date.

Get more information on Edwards Lifesciences and free access to the in-depth equity report at:
www.FiveStarEquities.com/EW

Merck & Co., Inc. (NYSE: MRK) shares declined 2.64 percent to close at $45.31 a share Monday. The stock traded between $45.21 and $45.82 on volume of 21.63 million shares traded. The company reported GAAP EPS was $0.38 for the third quarter of 2013, compared to $0.56 a year ago. Shares of Merck & Co. have gained approximately 10.0 percent year-to-date.

Get more information on Merck & Co. and free access to the in-depth equity report at:
www.FiveStarEquities.com/MRK

Zogenix, Inc. (NASDAQ: ZGNX) shares declined 6.25 percent to close at $2.85 a share Monday. The stock traded between $2.81 and $3.44 on volume 9.74 million shares traded. The company announced that Zohydro ER (hydrocodone bitartrate) extended-release capsules have received approval from the FDA. Shares of Zogenix have gained approximately 115.0 percent year-to-date.

Get more information on Zogenix free access to the in-depth equity report at:
www.FiveStarEquities.com/ZGNX

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Five Star Equities
info@fivestarequities.com